Algeta to Participate in Upcoming Investor Conference OSLO, NORWAY -- (Marketwired) -- 04/17/13 -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference: Kempen & Co. 6(th) Healthcare/Life Sciences Conference Date: 23 April 2013 Participants: Thomas Ramdahl (Chief Technology Officer) Renate Birkeli (IR) Venue: Amsterdam, The Netherlands About Algeta Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. Algeta to Participate in Upcoming Investor Conference: http://hugin.info/134655/R/1693399/556601.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE [HUG#1693399] For further information, please contact: Mike Booth / Renate Birkeli +47 23 00 67 32 Communications & Corporate Affairs firstname.lastname@example.org Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson email@example.com Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton firstname.lastname@example.org Kari Watson +1 781 235 3060 MacDougall Biomedical Communications email@example.com US investor enquiries: Tricia Swanson +1 646 378 2953 The Trout Group firstname.lastname@example.org
Algeta to Participate in Upcoming Investor Conference
Press spacebar to pause and continue. Press esc to stop.